Teva: Payers Hold The Cards On Material 2023 Adalimumab Opportunity
Company ‘Would Be Disappointed If It’s Not A Material Event In 2023’
Executive Summary
Fresh from partner Alvotech resolving patent litigation in the US for its proposed Humira biosimilar, Teva management has detailed the firm’s expectations around the product and the crucial issue of supply.
You may also be interested in...
Teva Identifies Teriparatide Importance Amid US Launch Drought
Teva acknowledged that it was “not independent of the macro environment in the US,” as it saw another significant drop off for its North America generics business amid a lack of new launches. The Israeli giant took the unusual step of singling out a complex generic asset – its proposed generic to Eli Lilly’s Forteo – as “the most important” potential launch for its 2022 top line.
Stada Gears Up For Higher-Strength Adalimumab As Alvotech Clears Up Legal Overhang
Alvotech and its strategic partner Stada are preparing to launch their higher-strength adalimumab candidate AVT02 in Europe after settling intellectual property disputes with originator AbbVie.
Alvotech Humira Settlement Sets Up Interchangeable Adalimumab Showdown
Alvotech and AbbVie have settled all of their legal disputes over Alvotech’s AVT02 biosimilar rival to Humira. With Alvotech seeking a coveted interchangeability designation for its higher-strength adalimumab, the firm’s US entry date provided by the settlement matches that of Boehringer Ingelheim’s interchangeable Cyltezo lower-strength adalimumab biosimilar.